Scarica l'app Stockscreener
107.17
4.76%
-5.36
Precedente Chiudi:
$112.53
Aprire:
$110.21
Volume 24 ore:
441.21K
Relative Volume:
0.59
Capitalizzazione di mercato:
$7.38B
Reddito:
$217.17M
Utile/perdita netta:
$-202.68M
Rapporto P/E:
-46.54
EPS:
-2.3028
Flusso di cassa netto:
$-156.63M
1 W Prestazione:
-2.57%
1M Prestazione:
-0.81%
6M Prestazione:
+15.57%
1 anno Prestazione:
+2.82%
Intervallo 1D:
$107.09
$114.75
Intervallo di 1 settimana:
$107.09
$114.75
Portata 52W:
$74.50
$122.20
Rhythm Pharmaceuticals Inc Stock (RYTM) Company Profile
Nome
Rhythm Pharmaceuticals Inc
Settore
Industria
Telefono
857-264-4280
Indirizzo
222 BERKELEY STREET, BOSTON, MA
Compare RYTM vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
RYTM
Rhythm Pharmaceuticals Inc
|
107.17 | 7.50B | 217.17M | -202.68M | -156.63M | -2.3028 |
VRTX
Vertex Pharmaceuticals Inc
|
541.69 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
794.19 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,023.21 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
137.99 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
207.88 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Rhythm Pharmaceuticals Inc Stock (RYTM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-19 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-11-25 | Iniziato | Citigroup | Buy |
| 2025-11-05 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-07-10 | Iniziato | Goldman | Buy |
| 2025-07-07 | Iniziato | Leerink Partners | Outperform |
| 2025-04-07 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-03-05 | Ripresa | Stifel | Buy |
| 2025-01-02 | Iniziato | Jefferies | Buy |
| 2024-12-20 | Iniziato | Oppenheimer | Outperform |
| 2024-10-21 | Iniziato | Guggenheim | Buy |
| 2024-09-18 | Iniziato | H.C. Wainwright | Buy |
| 2024-09-17 | Iniziato | JMP Securities | Mkt Outperform |
| 2024-05-08 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-08-01 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-01-18 | Ripresa | Canaccord Genuity | Buy |
| 2022-08-08 | Aggiornamento | Goldman | Neutral → Buy |
| 2022-08-05 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2022-06-17 | Reiterato | Needham | Buy |
| 2022-03-02 | Ripresa | Stifel | Buy |
| 2022-02-17 | Aggiornamento | Ladenburg Thalmann | Neutral → Buy |
| 2021-12-08 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-14 | Ripresa | Goldman | Neutral |
| 2021-08-04 | Downgrade | BofA Securities | Neutral → Underperform |
| 2021-08-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2020-11-30 | Downgrade | BofA Securities | Buy → Neutral |
| 2020-01-08 | Iniziato | Goldman | Sell |
| 2019-07-12 | Aggiornamento | Stifel | Hold → Buy |
| 2019-07-08 | Iniziato | Canaccord Genuity | Buy |
| 2019-03-13 | Iniziato | Ladenburg Thalmann | Buy |
| 2018-09-07 | Ripresa | Morgan Stanley | Overweight |
| 2018-06-25 | Reiterato | Needham | Buy |
| 2018-06-15 | Reiterato | Needham | Buy |
| 2017-10-30 | Iniziato | BofA/Merrill | Buy |
| 2017-10-30 | Iniziato | Needham | Buy |
Mostra tutto
Rhythm Pharmaceuticals Inc Borsa (RYTM) Ultime notizie
Blue Owl Capital Holdings LP Invests $6.82 Million in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
TD Cowen Names Rhythm Pharmaceuticals Its Top Pick Following Robust Q2 Results - StockInvest.us
Rhythm Pharmaceuticals (RYTM) grants CMO 50K options expiring 2036 - Stock Titan
Rhythm (RYTM) CMO reports no company stock holdings - Stock Titan
Rhythm Pharmaceuticals (RYTM) Stock Looks Pricey Following Strong IMCIVREE News - Sahm
Rhythm Pharmaceuticals Announces Appointment of Manher (AJ) Joshi as Chief Medical Officer - Sahm
Rhythm Pharmaceuticals: Building A Defensive MC4R Franchise (NASDAQ:RYTM) - Seeking Alpha
Rhythm Pharma files Form 3 for Chief Medical Officer Manher Joshi - Bitget
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock - Investing.com
Rhythm Pharmaceuticals CTO Joseph Shulman sells $608,210 of stock By Investing.com - Investing.com India
Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Alastair Garfield Sells 7,763 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) Insider Sells 5,079 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock By Investing.com - Investing.com Canada
Rhythm Pharmaceuticals CSO Alastair Garfield sells $912,703 in stock - Investing.com
Rhythm (NASDAQ: RYTM) CTO sells 5,079 shares in 10b5-1 plan - Stock Titan
Rhythm Pharmaceuticals Eyes AHO Growth, Global IMCIVREE Expansion and Pipeline Catalysts - NewsBreak: Local News & Alerts
Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer - TradingView
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: Exploring a 22.56% Potential Upside on Robust Analyst Confidence - DirectorsTalk Interviews
BRIEF-Rhythm Pharmaceuticals Announces Appointment Of Manher (Aj) Joshi As Chief Medical Officer - Bitget
Enterprise value to revenue forward of Rhythm Pharmaceuticals, Inc. – DUS:1RV - TradingView
Rhythm Pharmaceuticals(RYTM.US) Officer Sells US$8.9 Million in Common Stock - Moomoo
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock By Investing.com - Investing.com Nigeria
Rhythm Pharmaceuticals EVP Jennifer Kayden Lee Executes Stock Options and Sells Shares Under 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals EVP Yann Mazabraud Executes Stock Option and Sells Shares Under Rule 10b5-1 Plan - Kalkine Media
Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Yann Mazabraud Sells 57,000 Shares - MarketBeat
Insider Selling: Rhythm Pharmaceuticals (NASDAQ:RYTM) EVP Sells 75,834 Shares of Stock - MarketBeat
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock By Investing.com - Investing.com Australia
Rhythm Pharmaceuticals EVP Mazabraud sells $6.6m in stock - Investing.com
Rhythm Pharmaceuticals EVP, Jennifer Lee, sells $8.9m in stock - Investing.com
Rhythm Pharmaceuticals (RYTM) EVP exercises 56,601 options and sells 75,834 shares - Stock Titan
Rhythm Pharmaceuticals (RYTM) EVP sells 57K shares after $6.80 option exercise - Stock Titan
Rhythm Pharmaceuticals (RYTM) Q2 2026 Earnings Call Transcript - AOL.com
Dimensional Fund Advisors LP Sells 12,867 Shares of Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
How Investors Are Reacting To Rhythm Pharmaceuticals (RYTM) UK Orphan Expansion For IMCIVREE In Hypothalamic Obesity - Sahm
RHYTHM PHARMACEUTICALS, INC. SEC Filing (Aug 13, 2026) - Stock Titan
RYTM (NASDAQ: RYTM) investor plans sale of 5,079 shares worth $597K - Stock Titan
RYTM (RYTM) insider plans Form 144 sale of option and RSU shares - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Trading the Move, Not the Narrative: (RYTM) Edition - Stock Traders Daily
Rhythm Pharmaceuticals (RYTM) plans 57,000-share stock sale via broker - Stock Titan
Rhythm Pharmaceuticals (RYTM) Advances 2.94% to $116.16 as Bullish Momentum BuildsLong Setup Ideas - vinanet.vn
Why Is Rhythm Pharmaceuticals Stock Trading Higher On Wednesday? - TradingView
Rhythm Pharmaceuticals at Canaccord Genuity: launch gains widen - Investing.com
Rhythm Pharmaceuticals (RYTM) Slips 2.28% to $112.84 as Shares Hold Mid-RangeETH Profile - vinanet.vn
Bank of America Corp DE Grows Stake in Rhythm Pharmaceuticals, Inc. $RYTM - MarketBeat
Rhythm Pharmaceuticals (RYTM) insider outlines 10b5-1 stock sale plan in Form 144 - Stock Titan
Rhythm Pharmaceuticals, Inc. (RYTM) stock price, news, quote and history - Yahoo Finance UK
Rhythm Pharmaceuticals Announces IMCIVREE® (setmelanotide) Receives Expanded Marketing Authorization in the United Kingdom for Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury - The Manila Times
Rhythm Pharmaceuticals Announces UK MHRA Expansion of IMCIVREE for Acquired Hypothalamic Obesity - Quiver Quantitative
Rhythm's IMCIVREE authorized in UK for obesity after hypothalamic injury - Stock Titan
Analysts Have Conflicting Sentiments on These Healthcare Companies: Orthofix Medical (OFIX), Rhythm Pharmaceuticals (RYTM) and Viatris (VTRS) - The Globe and Mail
Rhythm Pharmaceuticals Inc Azioni (RYTM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Rhythm Pharmaceuticals Inc Azioni (RYTM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Shulman Joseph | Chief Technical Officer |
Aug 13 '26 |
Sale |
119.75 |
5,079 |
608,210 |
15,915 |
| Garfield Alastair | Chief Scientific Officer |
Aug 13 '26 |
Sale |
117.57 |
7,763 |
912,703 |
2,295 |
| Lee Jennifer Kayden | EVP, Head of North America |
Aug 13 '26 |
Option Exercise |
17.62 |
56,601 |
997,037 |
75,834 |
| Lee Jennifer Kayden | EVP, Head of North America |
Aug 13 '26 |
Sale |
117.38 |
75,834 |
8,901,531 |
0 |
| Mazabraud Yann | EVP, Head of International |
Aug 12 '26 |
Option Exercise |
6.80 |
46,625 |
317,050 |
112,655 |
| Mazabraud Yann | EVP, Head of International |
Aug 12 '26 |
Sale |
116.15 |
57,000 |
6,620,575 |
55,655 |
8.37%
0.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):